Board of Directors

Lisa Evrén

Ms. Evrén is the former Vice President and Treasurer at Talisman-Energy in Calgary. Prior to her entry into the energy industry, Ms. Evrén was the EVP and CFO of Merrimack Pharmaceuticals in Massachusetts, a privately held specialty pharmaceutical company focused in oncology. Previous to Merrimack, Ms. Evrén held roles of increasing responsibility in finance at Amgen and Pfizer. Ms. Evrén is advising Inhibikase on deal terms and financial positioning and aiding in financial modeling for the Company’s lead indications.

Richard Fante

Richard Fante has served as Chief Commercial Officer and Head of Business Development for Innocoll, Inc. since August 2015 and as President of RF Consulting LLC since April 11, 2013. Prior to founding RF Consulting, Mr. Fante spent over nineteen years at AstraZeneca pharmaceuticals in the United States. He served in a number of roles, most recently as President US, CEO North America and Regional Vice President of the Americas. Prior to assuming his role as President AstraZeneca US in November 2008, Mr. Fante served as the head of Brand Strategy and Portfolio Operations at AstraZeneca. Before joining AstraZeneca in January 1995, Mr. Fante worked at Lederle Laboratories where he started his career as a sales representative. Mr. Fante served as Board Chairman of the National Pharmaceutical Council (2012) and was a member of the Institute of Medicine of the National Academies of Science Roundtable on Value and Science. Mr. Fante holds a BA in Biology from Princeton University and an MBA from the University of North Carolina Chapel Hill. Mr. Fante’s qualifications to serve on the Board of Directors include his experience as a pharmaceutical executive and his leadership in the development and commercialization of pharmaceutical products including Crestor®, Seroquel®, Nexium®, and Symbicort®.

Hilary M. Malone, Ph.D.

Dr. Malone is an experienced business leader in the pharmaceutical industry with specialist expertise in global regulatory affairs and compliance spanning the development, registration, and marketing of innovative prescription drugs and vaccines. Dr. Malone currently serves as Chief Regulatory Officer and Head of Global Regulatory Affairs for Sanofi, a position she has held since 2013. Prior to joining Sanofi, Dr. Malone was the Chief Regulatory & Compliance Officer for Reata Pharmaceuticals, a small US-based biotech company. Dr. Malone has also held roles as the Senior Vice President and Head of Worldwide Regulatory Strategy for both Pfizer and Wyeth, overseeing all products across the human health businesses (pharmaceuticals and vaccines, consumer health brands, generics, and infant nutritionals). Earlier in her career, Dr. Malone held positions of increasing responsibility at SmithKline Beecham/GlaxoSmithKline and AstraZeneca. Dr. Malone earned her B.Sc.in Physiology and her Ph.D. in Molecular Neuropharmacology from the University of Dundee, Scotland, UK and also spent time in postdoctoral research at the University of California, San Francisco prior to joining the pharmaceutical industry. Dr. Malone was a leader in the development and commercialization of a number of pharmaceutical products including Avandia®, Pristiq®, Sutent®, Toujeo®, Crestor®, Prevnar 13®, Praluent®, and Lemtrada®. Her experience as a pharmaceutical executive and regulatory expert will be invaluable as Inhibikase advances discussions with U.S., European, and other global regulatory authorities regarding the pathway for development, approval, and commercialization of the company’s novel products.

Peter Mueller, PhD.

Dr. Mueller is President of the Mueller Health Foundation, a private foundation tackling globally lethal infectious diseases such as tuberculosis. Previously, he was President of R&D and Chief Scientific Officer of Axcella Health. Prior to Axella Health, Dr. Mueller served as Executive Vice President Global Research and Development & Chief Scientific Officer for Vertex Pharmaceuticals, where he provided strategic oversight for Vertex’s worldwide drug discovery research programs, pharmaceutical development, quality assurance and control, and pharmaceutical operations as well as clinical and nonclinical development, regulatory, patient safety, and medical affairs. At Vertex, Dr. Mueller was a leader in the successful approval and launch of Incivek®, the NDA/MAA submission and commercial launch of Kalydeco®, and several proof of clinical concept candidates in various disease areas. Prior to his tenure at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company’s worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates and held several positions in basic research, medicinal chemistry, and management in different centers of BI worldwide.

Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.

Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies.

He is a board member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (UK); US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Harvard Accelerator Fund. Before he left Connecticut to join Vertex, Dr. Mueller was also a member of Govenor Roland’s Council on Economic Competitiveness and Technology for the State of Connecticut (USA).

Dr. Mueller’s qualifications to serve on the Board of Directors include his experience as a pharmaceutical executive and his leadership in the development and commercialization of pharmaceutical products including Spireva®, Atrovent HFA®, Kalydeco®, Combivent®, Incivek®, and Orkambi®.

Milton H. Werner, Ph.D.

Prior to founding Inhibikase, Dr. Werner rebuilt research at the cell-free immunotherapeutics company Celtaxsys in Atlanta, Georgia. At Celtaxsys, Dr. Werner drove the research program from the loss of its technology license to a $20 million pre-money valuation at the opening of the Company’s Series B investment round. Celtaxsys explores the role of proteins in controlling immune cell migration. Previous to Celtaxsys, Dr. Werner was an internationally recognized scientist, Associate Professor and Head of Lab at the Rockefeller University. At the Rockefeller, Dr. Werner focused on elucidating mechanisms of human disease in immunology, oncology, and infectious disease.

Dr. Werner received his Ph.D. in Chemistry from the University of California, Berkeley and trained at the National Institutes of Health before joining the Rockefeller in 1996. He is the author of more than 70 research articles, reviews, book chapters and has given lectures on his research work on more than 150 occasions throughout the world. He is recipient of numerous private and public research grants totaling more than $10 million. Dr. Werner is also the recipient of several awards, including the Young Investigator Award from the Sidney Kimmel Cancer Foundation, the Research Chair from the Brain Tumor Society and a $1 million prize from the W. M. Keck Foundation.

Back to Top